Suchergebnisse - "Melkadze, Tamar"

PubPharm (9)

1

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

2

Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer : Patient-reported outcomes from phase 3 EMPOWER-Lung 3

enthalten in: Cancer | 2023

von Makharadze, T. | Quek, R. | Melkadze, T. | +16

3

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC : 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Makharadze, T. | Gogishvili, M. | Melkadze, T. | +17

CommentIn: J Thorac Oncol. 2023 Jul;18(7):e72-e73. - PMID 37348996

4

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer : a randomized, controlled, double-blind phase 3 trial

enthalten in: Nature medicine | 2022

von Gogishvili, M. | Melkadze, T. | Makharadze, T. | +23

5

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer : The ASTRUM-005 Randomized Clinical Trial

enthalten in: JAMA | 2022

von Cheng, Y. | Han, L. | Wu, L. | +106

CommentIn: JAMA. 2022 Sep 27;328(12):1205-1207. - PMID 36166047

6

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kelley, R. | Rimassa, L. | Cheng, A. | +19

CommentIn: Lancet Oncol. 2022 Aug;23(8):962-963. - PMID 35798015

7

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer : An Open-Label Phase II Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von O'Malley, D. | Neffa, M. | Monk, B. | +12

CommentIn: J Clin Oncol. 2022 Jul 1;40(19):2177-2178. - PMID 35486885

8

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer : A Randomized, Double-Blind, Phase III Study (STELLA)

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2021

von Trukhin, D. | Poddubskaya, E. | Andric, Z. | +96

9

Advanced Esophageal Squamous Cell Carcinoma in Young Female Patient With Durable Complete Response on Treatment

enthalten in: Cureus | 2021

von Jankarashvili, N. | Melkadze, T. | Tchiabrishvili, M. | +2

1
[1]